Screener
Kymera Therapeutics KYMR Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from stock option exercises | 32,577 | 8,237 |
| Proceeds from employee stock purchase plan | 1,472 | 1,112 |
| Payments on finance leases | (861) | (659) |
| Net cash provided by financing activities | $33,188 | $245,984 |
| Net decrease in cash, cash equivalents and restricted cash | (232,512) | 215,586 |
| Cash, cash equivalents and restricted cash at beginning of period | 362,811 | 126,050 |
| Cash, cash equivalents and restricted cash at end of period | $130,299 | $341,636 |
| Supplemental disclosure of cash flow activities |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's financing cash flow?
- Kymera Therapeutics (KYMR) reported financing cash flow of $14.42M in Q2 2026.
- How has Kymera Therapeutics's financing cash flow changed year-over-year?
- Kymera Therapeutics's financing cash flow decreased by 94.1% year-over-year, from $245.73M to $14.42M.
- What is the long-term trend for Kymera Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Kymera Therapeutics's financing cash flow has grown at a 41.1% compound annual growth rate (CAGR), from $250.28M to $990.71M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Kymera Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude